Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

From the deep sea to the shallow seafloor, researchers are uncovering unusual sugars that do something extraordinary to ...

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

Arcus’s highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal cell ...

A study published in the International Journal of Molecular Sciences reports that a cannabis extract reduced cell growth, ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

A microscopic parasite that can live for decades in the human brain infects an estimated one-third of the world's population ...

Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite ...

Cells have the remarkable ability to initiate their own death through a mechanism called programmed cell death, also known as apoptosis. Apoptosis contains sophisticated signalling pathways and ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...